Measuring symptom burden in patients with cancer during a pandemic: the MD Anderson symptom inventory for COVID-19 (MDASI-COVID)

Journal of Patient-Reported Outcomes

Table 5 Concurrent Validity of the MDASI-COVID Subscales

MDASI-COVID	Pearson correlation with the EQ-5D-5 L utility index	Pearson correlation with the EQVAS
Core	–0.674	–0.510
Module (11 Items)	–0.518	–0.403
Module (14 Items) ^a	–0.531	–0.396
All symptoms (24 items)	–0.624	–0.470
All symptoms (27 items) ^a	–0.616	–0.428
Interference	–0.699	–0.561
WAW	–0.695	–0.553
REM	–0.648	–0.526

Higher scores in the EQ-5D-5 L denote better outcome. All correlations were significant at P < .05
^a Subset of sample (n = 351 patients responding to 3 symptoms added in October 2020)
Abbreviations: COVID, novel coronavirus disease 2019; EQ-5D-5 L, EuroQOL 5 Dimensions 5 Levels; EQ-VAS, EQ-5D-5 L visual analog scale; MDASI, MD Anderson Symptom Inventory; REM, composite of the interference items relations with other people, enjoyment of life, and mood; WAW, composite of the interference items work, general activity, and walking